Patent US6965025B2 successfully refreshed from Google Patents.
US6965025B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antisense modulation of connective tissue growth factor expression
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 2001-12-10
•
Granted: 2005-11-15
•
Expires: 2021-12-10
Abstract
Abstract Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
Inventors
- 👤 William Gaarde
- 👤 Andrew T. Watt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 19:47
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1136; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/33; C12N2310/334; C12N2310/3341; C12N2310/34; C12N2310/341; C12N2310/346; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/582
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
86 words
A compound 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said compound specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor, wherein said compound is an antisense oligonucleotide and wherein said antisense oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar moiety, and a modified nucleobase.
Claim 2
Dependent Claim
86 words
A compound 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said compound specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor, wherein said compound is an antisense oligonucleotide and wherein said antisense oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar moiety, and a modified nucleobase.
Claim 3
Dependent Claim
69 words
An antisense oligonucleotide up to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:47, 48, 63, or 64.
Claim 4
Dependent Claim
69 words
An antisense oligonucleotide up to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:47, 48, 63, or 64.
Claim 5
Dependent Claim
16 words
The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
Claim 6
Dependent Claim
14 words
The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
Claim 7
Dependent Claim
16 words
The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
Claim 8
Dependent Claim
15 words
The compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
Claim 9
Dependent Claim
15 words
The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
Claim 10
Dependent Claim
12 words
The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
Claim 11
Dependent Claim
62 words
An antisense oligonucleotide 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide is a chimeric oligonucleotide.
Claim 12
Dependent Claim
62 words
An antisense oligonucleotide 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide is a chimeric oligonucleotide.
Claim 13
Dependent Claim
15 words
A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
Claim 14
Dependent Claim
11 words
The composition of claim 10 further comprising a colloidal dispersion system.
References Cited (Backward Citations)
US5585270A
Cited
US5783187A
Cited
US6069006A
Cited
US6150101A
Cited
US6232064B1
Cited
US5876730A
Cited
WO1999066959A2
Cited
WO2000013706A1
Cited
WO2000027868A2
Cited
WO2000035936A1
Cited
WO2001029217A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-11-14 | 2009-05-16 | 2009-11-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-11-14 | 2013-05-16 | 2013-11-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-11-14 | 2017-05-16 | 2017-11-15 | $7700.00 | Window Closed / Lapsed |